Clinical Trial Update: A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma [Phase 2]

View source ↗

Summary

Phase II study of Futibatinib in combination with Pembrolizumab for metastatic microsatellite-stable endometrial carcinoma was terminated; results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinoma

Drugs mentioned

• Futibatinib (futibatinib)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Cancer, Endometrium Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-09-17